Women more likely to need walking aids but less likely to use them – study
Man Of The Moment Balthazar Ignores Social Media Trolls, Goes To A Restaurant With His Family To Have Good Timegremlin BlackBerry Overview Since mid-year 2024, BlackBerry Limited ( NYSE: BB ) shares traded in a narrow range of $2.15-$2.30. More recently, after November 22, 2024, BB stock broke out from $2.35 to trade at around $3.49 at the time of writing. The neglected Canadian firm, which has a Please [+] Follow me for coverage on deeply discounted stocks. To get more beyond these articles, get do-it-yourself tips and tricks in three ways: Subscribe to the Free DIY Tier to get a preview of the subscription. Read dozens of articles. This is completely separate from the alerts you get when following me. The Basic tier is the entry level, no-frills stock list. The Full Service is for readers who want access to five stock models, live online chat, and timely, actionable, stock alerts. Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more. Top Pick this year : this stock has become the best ever top pick . Highlighted is the one-day change, the editor's pick, and daily gain. The returns from the public articles are: 2023 Average Return: 8.4% 2022 Average Return: 6.9% 2021 Average Return 29.90% 2020 Average Return: 49.9% Flagship Products: 1. Top DIY Picks: Undervalued stocks have upcoming catalysts that markets do not expect. 2. Dividend-income Champs that have a long history of dividend growth. Includes printable calendar and quantitative scores. 3. DIY Risky Picks for a speculative allocation positive momentum for up to a moonshot, triple return. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Breaking the social care reform logjam | Letters
The new research from eye care nonprofit Orbis International, supported by Heidelberg Engineering, shows how telemedicine improves outcomes for children with retinoblastoma through e-learning and virtual mentorship NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Orbis International announces new research that finds telemedicine can improve care for children with retinoblastoma, a form of childhood cancer that can lead to blindness. The study, published in JCO Global Oncology , is the first to show that virtual mentor-mentee relationships through Cybersight , Orbis's free telemedicine and e-learning platform, not only improves lives, but can save them by successfully transferring skills to eye care professionals in low- and middle-income countries. Each year, about 9,000 children worldwide are diagnosed with retinoblastoma, but only 40% survive beyond three years. This is because 92 percent of these children live in low-and-middle-income countries, where retinoblastoma patients face late diagnosis and limited access to eye care. This groundbreaking research was supported by Heidelberg Engineering, a global leader in advanced imaging solutions. Their funding has been crucial in delivering e-learning webinars, alongside advancing research through Orbis's Cybersight platform. "Retinoblastoma can be treated if caught early, but too often, it's not diagnosed until it's too late," said Dr. Hunter Cherwek , Vice President of Clinical Services and Technologies at Orbis International. "Many low- and middle-incomes countries don't have enough resources to provide proper care, but technology offers a solution. This study shows that telemedicine can improve health outcomes for children, especially in remote areas where pediatric eye doctors are scarce." Cybersight has long been used to diagnose and treat diabetic retinopathy, retinopathy of prematurity, and other eye diseases, but this is the first research on its impact on retinoblastoma. The groundbreaking study explored whether Cybersight Consult – a component of the Cybersight platform that connects mentee doctors with expert mentors for advice on complex clinical cases – could improve care and treatment for retinoblastoma. Researchers also examined how virtual mentoring helps eye care professionals build expertise in retinoblastoma over time. Researchers conducted a retrospective review of 653 Cybersight retinoblastoma consultations undertaken by 38 different mentees from 2004 to 2023. They found significant improvements in knowledge-sharing over this 20-year period, especially in three areas: understanding and recording patient symptoms, classifying the disease's type and how advanced it is, and the results of treatment for both the patient and their eye health. Cybersight's virtual mentorship approach helped mentees gain critical skills to treat retinoblastoma, especially in regions with few eye care resources. Cybersight provides training, mentoring, and online courses to eye care professionals around the world. The platform has helped train eye care professionals in nearly every country and territory and counts around 15% of the world's ophthalmologists as registered users. The study reveals the potential of using communication and digital technologies to help children around the world see – and survive. About Orbis International Orbis is an international nonprofit delivering sight-saving programs in over 200 countries and territories worldwide so that individuals, families, and communities can thrive. Currently, around 1 billion people across the globe live with completely avoidable blindness and vision loss. For over four decades, Orbis has been tackling this challenge by building strong and sustainable eye care systems that leave a lasting legacy of vision. Orbis runs dedicated in-country programs in Africa , Asia , the Caribbean , and Latin America ; develops and implements innovative training and technology, including an award-winning telemedicine and e-learning platform, Cybersight ; and operates the world's first and only Flying Eye Hospital , a fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. For the past 11 consecutive years, Orbis has achieved Charity Navigator 's coveted four-star rating for demonstrating strong financial health and commitment to accountability and transparency, placing Orbis in the top 3% of U.S. charities. For the past three years, Orbis has earned GuideStar 's platinum Seal of Transparency. Since 2022, Orbis has earned "accredited charity" status from the Better Business Bureau by meeting all 20 of their standards for charity accountability. To learn more, please visit orbis.org . MEDIA CONTACT Jenna Montgomery Manager, Global Communications and Marketing jenna.montgomery@orbis.org View original content to download multimedia: https://www.prnewswire.com/news-releases/study-finds-telemedicine-improves-care-for-children-with-eye-cancer-302337562.html SOURCE Orbis International